Nexium News
Most Popular Nexium Story
Can AstraZeneca continue to swear off major M&A?
Can AstraZeneca ($AZN) CEO David Brennan stick to his no-megadeals diet? Analysts are beginning to wonder, says Bloomberg, now that three of the company's promising drug candidates have stumbled. The Read more...
Latest Headlines
- January 20, 2012
- December 8, 2011
- November 7, 2011
- September 6, 2011
- August 25, 2011
- August 2, 2011
- July 26, 2011
- July 1, 2011
- June 15, 2011
- June 13, 2011
- December 16, 2010
- December 3, 2010
- November 11, 2010
- October 29, 2010
- June 1, 2010
- January 7, 2010
- March 26, 2009
- November 12, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
